From the Research
The maximum recommended dose of Neupro (rotigotine transdermal patch) is 8 mg/24 hours for Parkinson's disease and 3 mg/24 hours for Restless Legs Syndrome (RLS). When determining the maximum dosage, it's crucial to consider the condition being treated and the individual patient's response to the medication. According to the most recent and highest quality study available, 1, the pharmacokinetics of rotigotine transdermal patch are similar in healthy subjects, patients with early- or advanced-stage PD, and patients with RLS.
Key Considerations for Neupro Dosage
- The medication should be applied once daily to clean, dry, intact skin.
- The patch should be rotated to a different site each day to minimize skin reactions.
- It's essential to start at a lower dose and gradually increase to the effective dose under medical supervision.
- The medication works by stimulating dopamine receptors in the brain, helping to improve motor function in Parkinson's disease or reduce uncomfortable sensations in RLS.
- Side effects may include skin reactions at the application site, nausea, somnolence, and dizziness.
Important Safety Information
- Patients should not stop Neupro suddenly as this could lead to withdrawal symptoms.
- The dose should be tapered gradually when discontinuing treatment, as recommended by 2.
- The use of Neupro as a transdermal patch bypasses the gastrointestinal tract, making it a treatment option for patients with dysphagia, as noted in 2.
Overall, the maximum dosage of Neupro should be determined based on the individual patient's needs and response to the medication, with careful consideration of the potential benefits and risks, as discussed in 1 and 2.